Palladon (Hydromorphone Hydrochloride)

Hydromorphone Hydrochloride, the active ingredient in Palladon, is an opioid analgesic presented as a strength/form for oral use. It is indicated for the management of moderate to severe pain in adult patients when alternative treatments are inadequate.

GNH USA supplies Palladon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Hydromorphone Hydrochloride is an opioid that acts on the central nervous system to relieve pain across several clinical settings. - Acute postoperative pain: provides rapid analgesia following surgery. - Cancer‑related pain: helps control persistent pain associated with malignant disease. - Severe chronic non‑cancer pain: used when other analgesics are insufficient.

Adverse reactions may occur with hydromorphone use and should be monitored.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Constipation: reduced bowel motility leading to hard stools. - Drowsiness or sedation: increased sleepiness or reduced alertness. - Dizziness: sensation of light‑headedness or imbalance. - Dry mouth: reduced salivation causing oral discomfort. - Sweating: increased perspiration without exertion.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that can be life‑threatening. - Severe hypotension: marked drop in blood pressure. - Bradycardia: unusually slow heart rate. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Confusion or delirium: altered mental status. - Dependence or withdrawal: signs of physical dependence with prolonged use.

When prescribing hydromorphone, clinicians should consider several safety factors. - Assess pain severity: confirm that opioid therapy is appropriate for the level of pain. - Evaluate patient history: screen for respiratory disorders, head injury, or substance abuse. - Monitor for sedation: watch for excessive drowsiness, especially when combined with other CNS depressants. - Adjust for renal/hepatic impairment: dose may need modification in patients with organ dysfunction. - Educate on constipation: advise prophylactic laxatives and fluid intake. - Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Hydromorphone may interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Benzodiazepines: combined use can cause profound respiratory depression. - Other opioids: additive central nervous system depression increases overdose risk. - CNS depressants (e.g., barbiturates, alcohol): may intensify sedation and respiratory effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise hydromorphone plasma levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce analgesic effect. - Anticholinergic agents: may worsen constipation. - Diuretics: can enhance hypotensive effects. - Serotonergic drugs: risk of serotonin syndrome when combined with certain antidepressants.